What is the process for using intravenous ketamine to treat major depressive disorder with acute suicidal ideation?

IV Ketamine for MDD with Acute Suicidal Ideation: Clinical Process

Intravenous ketamine should be used as an adjunctive treatment for short-term reduction of suicidal ideation in patients with major depressive disorder and acute suicidal thoughts, administered at 0.5 mg/kg over 40 minutes in a monitored setting, with effects typically observed within 24 hours but lasting only up to 7 days. 1

Patient Selection Criteria

Reserve ketamine for patients who have failed at least 2 adequate trials of antidepressant medications - it is not recommended as initial treatment. 1 The 2022 VA/DoD guidelines specifically support ketamine infusions as adjunctive therapy for patients with both MDD and suicidal ideation, though the evidence base primarily comes from treatment-resistant depression populations. 1

Key Eligibility Considerations:

• Patients must have current major depressive disorder with clinically significant suicidal ideation 2
• Treatment-resistant depression (≥2 failed antidepressant trials) is the typical indication 1
• Patients should be medically stable for anesthetic administration 3

Pre-Treatment Requirements

Essential Safety Preparations:

• Must be administered by or under direction of physicians experienced in general anesthetics, airway management, and ventilation 3
• Emergency airway equipment must be immediately available 3
• Administer an antisialagogue prior to induction due to potential for salivation 3
• Consider benzodiazepine administration to prevent neuropsychological manifestations during emergence 3
• Ensure nil per os (NPO) guidelines have been followed, as vomiting and aspiration can occur despite active laryngeal-pharyngeal reflexes 3

Dosing Protocol

Standard Induction Dose:

Administer 0.5 mg/kg intravenously over 40 minutes - this is the most extensively studied regimen for suicidal ideation. 1, 2 The FDA label indicates the intravenous dose range is 1-4.5 mg/kg for anesthesia, but the psychiatric literature consistently uses 0.5 mg/kg. 3

Critical Dosing Details:

• Do NOT inject the 100 mg/mL concentration intravenously without proper dilution 3
• Dilute with equal volume of Sterile Water, Normal Saline, or 5% Dextrose 3
• Administer slowly over 40-60 minutes - rapid administration causes respiratory depression and enhanced vasopressor response 3
• Alternative infusion rate: 0.5 mg/kg/min 3

Repeat Dosing Strategy:

• Single infusions show effects lasting 24 hours to 7 days 1
• When ketamine is added to ongoing antidepressant treatment, significant improvements persist up to 7 days; as monotherapy, no significant differences at 7 days 1
• Serial infusions (up to 6-8 treatments over 2-4 weeks) can be administered twice weekly to maintain treatment gains 4, 5
• A subset receiving 6 infusions over 2 weeks maintained significant reduction in suicidal ideation for the treatment duration 4

Monitoring Requirements

During Infusion:

• Continuously monitor vital signs - ketamine increases blood pressure, heart rate, and cardiac output 3
• Blood pressure peaks 10-50% above baseline within minutes, usually returning to baseline within 15 minutes 3
• Monitor for respiratory depression, particularly with rapid administration 3
• Observe for dissociative symptoms, which are common but typically short-lived 5, 6

Post-Infusion Monitoring:

• Assess suicidal ideation at specific timepoints: 40 minutes, 90 minutes, 24 hours, and up to 7 days 4
• The most robust anti-suicidal effects occur at 24 hours post-infusion 1, 2
• In one emergency department study, 88% of ketamine recipients achieved remission of suicidal ideation at 90 minutes compared to 33% with placebo 7
• Depression symptom improvement peaks at 24 hours and persists at 3-4 day follow-up 1

Expected Clinical Outcomes

Efficacy Timeline:

• Suicidal ideation reduction begins within 1 hour (71.1% reduction) and persists up to 1 week (60.4% reduction) 8
• At 24 hours, the reduction in suicidal ideation is approximately 5 points greater on the Scale for Suicidal Ideation compared to active control (Cohen's d=0.75) 2
• Response rate (≥50% reduction in suicidal ideation) at 24 hours: 55% with ketamine vs 30% with midazolam (NNT=4.0) 2
• Depression symptom improvement occurs within 24 hours and persists for 3-4 days 1

Important Caveat on Specificity:

The anti-suicidal effect may be partially independent of overall antidepressant effects - patients whose mood did not respond still exhibited significantly less suicidal ideation than baseline. 8 However, this remains controversial, as some studies show the decrease in suicidal ideation is explained by overall reduction in depression symptoms. 4 The FDA has not established that esketamine (the S-enantiomer) prevents suicide or reduces suicidal behavior, only that it treats depressive symptoms in this population. 1

Common Adverse Effects

Expected Short-Term Side Effects:

• Increased heart rate and blood pressure 5, 6
• Headache and dizziness 5
• Dissociative symptoms (depersonalization/derealization, emotional disturbance) - these are common but typically resolve quickly and are not treatment-limiting 5, 6, 9
• Nausea/vomiting 9
• Dissociation severity significantly reduces with subsequent infusions compared to baseline 6

Serious Safety Concerns:

• Genitourinary pain has been reported in individuals with chronic ketamine use for off-label indications 3
• Consider cessation if genitourinary pain continues with other genitourinary symptoms 3
• No serious adverse events were reported in the acute suicidal ideation trials 7

Critical Limitations and Pitfalls

Evidence Gaps:

• Ketamine lacks long-term efficacy and safety trials in MDD 1
• The bulk of evidence is from patients with treatment-resistant depression, not specifically those with acute suicidal ideation 1
• Most studies excluded patients with "highly active" suicidal ideation 4
• The effectiveness in preventing suicide or reducing suicidal behavior has not been established 1

Duration of Effect:

The major limitation is the short duration of benefit - effects last only up to 7 days, particularly when used as monotherapy. 1 This necessitates:

• Concurrent optimization of standard antidepressant therapy 2
• Consideration of repeated infusions for maintenance 1
• Close follow-up and safety planning as effects wane 2

Practical Barriers:

• Requires specialized setting with anesthesia expertise and monitoring capabilities 3
• Unlike esketamine (intranasal), IV ketamine does not have formal REMS requirements, but similar safety precautions are necessary 1
• Access is limited to specialized centers with appropriate resources 1

Adjunctive Treatment Strategy

Ketamine should be used as an adjunct to ongoing antidepressant treatment, not as monotherapy. 1 When added to ongoing antidepressants, benefits persist longer (up to 7 days) compared to monotherapy. 1

Concurrent Interventions:

• Continue or optimize standard pharmacotherapy during and after ketamine treatment 2
• Consider benzodiazepine co-administration to reduce emergence phenomena 3
• Implement comprehensive suicide risk management and safety planning 2
• Clinical improvement can be maintained for up to 6 weeks with additional optimized standard pharmacotherapy in follow-up 2